Status:
RECRUITING
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
Lead Sponsor:
Yonsei University
Conditions:
Advanced Hepatocellular Carcinoma
Chemotherapy
Eligibility:
All Genders
19-80 years
Phase:
NA
Brief Summary
To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start S...
Detailed Description
The subjects with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and if they voluntarily agree to the cli...
Eligibility Criteria
Inclusion
- Age 19 to 80 years old
- Liver function Child-Pugh class A
- ECOG 0-1
- Patient clinically or pathologically diagnosed with hepatocellular carcinoma
- Advanced hepatocellular carcinoma that is inoperable
- Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy.
Exclusion
- Brain metastases
- Have a history of malignancy other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of metastasis or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)
- Subjects with a high probability of untreated gastric or esophageal varices or bleeding
- Serious uncontrolled medical comorbidities
- History of liver transplant surgery
- Autoimmune liver disease
Key Trial Info
Start Date :
May 28 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 27 2028
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06595108
Start Date
May 28 2024
End Date
March 27 2028
Last Update
November 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongin Severance Hospital
Yongin-si, South Korea, 365